About Us:
Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning Stanford University neurologist Lawrence Steinman, Ph.D. Since then, we have been developing treatments for rare and under-addressed diseases, sometimes in collaboration with other pharmaceutical companies.
Our foundational work began in neuroendocrine disorders with our co-founder Dr. Vale’s discovery and study of corticotropin-releasing factor (CRF), an important stress hormone that regulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. This work led to the understanding of key biological pathways involved in congenital adrenal hyperplasia (CAH), a rare, genetic, life-long and life-threatening disorder caused by an enzyme deficiency.
Address:
6027 Edgewood Bend Ct
San Diego, CA 92130
United States
Phone:
(877) 641-3461
Email: MedInfo@Neurocrine.com
Website: https://Neurocrine.com
Brief summary of the materials and/or video content:
Click to watch an animation of the mechanism of disease of classic congenital adrenal hyperplasia (CAH): https://neurocrine.box.com/shared/static/1gshgs2giq8096tds0f0cyxe7agup7c7.mp4
Click to watch an animation of the mechanism of action of crinecerfont: https://neurocrine.box.com/shared/static/1izke8z8nkc4klti6quu94pm7wzh9ndz.mp4
Please see the full Prescribing Information for CRENESSITY®(crinecerfont): https://www.neurocrine.com/crenessitypi
For more educational resources about CAH, including the latest disease state information and clinical study data, please visit NeurocrineMedical.com and create a user login account to access these resources.
Stay tuned for announcements throughout the year of educational virtual symposia about congenital adrenal hyperplasia.
Have questions? Please contact:
MedInfo@Neurocrine.com
1-877-641-3461
Enter the MAP Spotlight Raffle